Dr. Mary Hamby is vice president of research at Cognition Therapeutics. She received her PhD in biomedical science from the University of Connecticut and conducted postdoctoral training at the University of California Los Angeles. Her career comprises over 20 years of experience in the fields of neurodegenerative diseases and drug discovery in both academia and pharma/biotech. At Cognition Therapeutics, Dr. Hamby is focused on the discovery and development of disease-modifying therapeutics to help treat patients with age-related diseases including Parkinson’s disease, dementia with Lewy bodies, Alzheimer’s disease and other neurodegenerative diseases for which no such therapies exist. Dr. Hamby oversees the discovery and development of small molecule modulators that block the toxic effects of alpha-synuclein aggregates on neurons and leads research efforts aimed at advancing clinical candidates to IND-enabling studies. Dr. Hamby has experience in guiding the design of clinical trials, including for disorders related to abnormal aggregation of synucleins.